Parkinson's word collage.jpg
Parkinson's Disease

Drug for a Genetic Disease Slows Parkinson's

Research done at the University of California, Los Angeles discovered that a drug being evaluated to Gaucher disease, a rare genetic disorder, helped slow the progression of Parkinson’s disease in mice. The study was published in the October 2014 edition of the journal Neurotherapeutics.

A release from the university explains that that a drug called AT2101 improved motor function, stopped inflammation in the brain, and reduced levels of alpha-synuclein, which is a protein critically involved in Parkinson’s.

Although the exact cause of Parkinson’s is unknown, evidence points to an accumulation of alpha-synuclein, which has been found to be common to all people with the disorder. The protein is thought to destroy the neurons in the brain that make dopamine, a neurotransmitter that helps regulate a number of functions, including movement and coordination. Dopamine deficiency is associated with Parkinson’s disease.

Gaucher disease is a rare genetic disorder in which the body cannot produce enough of an enzyme called β-glucocerebrosidase, or GCase. Researchers seeking genetic factors that increase people’s risk for developing Parkinson’s have determined that there may be a close relationship between Gaucher and Parkinson’s due to a GCase gene. Mutation of this gene, which leads to decreased GCase activity in the brain, has been found to be a genetic risk factor for Parkinson’s, although the majority of patients with Parkinson’s do not carry mutations in the Gaucher gene.

The release quotes senior author Marie-Francoise Chesselet, the Charles H. Markham Professor of Neurology at UCLA and director of the UCLA Center for the Study of Parkinson’s Disease, as saying, “This is the first time a compound targeting Gaucher disease has been tested in a mouse model of Parkinson’s disease and was shown to be effective. The promising findings in this study suggest that further investigation of this compound in Parkinson’s disease is warranted.”

In the study, the researchers used mice that were genetically engineered to make too much alpha-synuclein which, over time, led the animals to develop deficits similar to those observed in humans with Parkinson’s. The researchers found that the mice’s symptoms improved after they received AT2101 for four months.

The researchers also observed that AT2101 was effective in treating Parkinson’s in mice even though they did not carry a mutant version of the Gaucher gene, suggesting that the compound may have a clinical effect in the broader Parkinson’s population.

AT2101 is a first-generation “pharmacological chaperone” — a drug that can bind malfunctioning, mutated enzymes and lead them through the cell to their normal location, which allows the enzymes to carry on with their normal work. This was the first time that a pharmacological chaperone showed promise in a model of Parkinson’s, according to Chesselet.

logo

The latest for the greatest!

Get up-to-the-moment health + wellness info
  right to your inbox, plus exclusive offers!